Kurin Announces Kurin Jet, A Quantum Leap Forward in Devices Designed to Address Blood Culture Contamination

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today the limited commercial release of Kurin Jet, a significant technological advance over Kurin’s own market-leading Kurin Lock®. The new ventless device is not at issue in the lawsuit with Magnolia Medical.

“We are excited to announce the introduction of Kurin Jet, a fundamentally different product that provides a new level of performance in addressing the blood culture contamination market” said Bob Rogers, CEO of Kurin, Inc. “Although our current Kurin Lock is the market leader because of its small size and passive, user-friendly design, we have leapfrogged that technology and created a much faster device with a greater level of control for clinicians. Kurin Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”

“Kurin Jet helps hospitals address the significant challenge of blood culture contamination with its unique design, speed, and ease of use. Based on its performance and feedback from those who have used Jet, we will limit the initial release, as demand will exceed initial production volumes. Full release will occur later this year.”

Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Like the Kurin Lock, Kurin Jet passively sidelines potential contaminants during blood culture collection. Kurin Lock and Kurin Jet both provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.